About: Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd. for the development of Amezalpat into a global first-line randomized study; and has a product development and investigator-initiated trial collaboration agreement with Heibei Senlang Biotechnology Co., Ltd. to develop TPST-4003 product candidate. Tempest Therapeutics, Inc. is headquartered in Brisbane, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $0.47 (-0.72%)
TPST NASDAQ Tempest Therapeutics Inc
Tempest Therapeutics Inc share price
TPST price activity
Last Price
$0.470
Change (24hr)
-0.00 USD (0.72%)
Volume
140.36K
Volume (4w avg)
-
Open
$0.50
Day Range
$0.46 - $0.50
Previous Close
$0.47
Last Trade
03 Nov, 9:20 pm GMT+0
Delayed
03 Nov, 9:20 pm GMT+0
TPST price performance
Delayed
03 Nov, 9:20 pm GMT+0
TPST details
TPST Market Signals